Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEND-CABG II: MC-1 in high-risk CABG
NCT00402506Phase 3Completed
- Sponsor
- Medicure Inc.
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Myocardial ischemia (MI) and reperfusion injury (IRI) comparing MC-1 with Placebo (2 arms). Primary endpoint: Combined incidence of cardiovascular death or nonfatal myocardial infarction at 30 days. Started Nov 2006; status: completed.
02
Drugs
Tardoxal
03
Conditions
Myocardial ischemia (MI)reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT00402506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00402506.